SAUREUS, INC.

Medtech · Private

Rapid diagnostic assay for C. difficile toxins using optimized latex bead agglutination platform with immobilized monoclonal antibodies

Grants
$265K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
2
0 granted · 2 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Developing a Z-domain based latex agglutination assay for C. difficile toxins$224,940
Federal grantDepartment of Health and Human Services · Phase I · Developing a Z-domain based latex agglutination assay for C. difficile toxins$40,000
Federal grant · SBIR/STTR

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
737MICROMED CARDIOVASCULAR INC—$11M
738ALEO BME INC——
739SCANOGEN INC.——
740SAUREUS, INC.——
741Brockman-Hastings LLC——
742ASTRADX INC——
743OrthoCor Medical, Inc.—$16K

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 2
  • System And Method For Detecting Clostridium Difficile Toxinsapplication
  • Assys For Bacterial Detection And Identificationapplication

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.